Regulus Therapeutics (RGLS) News Today $8.30 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$8.30 -0.01 (-0.06%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGLS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?Regulus Therapeutics (NASDAQ:RGLS) Share Price Crosses Above 200 Day Moving Average - Should You Sell?June 10 at 3:30 AM | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Sees Strong Trading Volume After Insider Buying ActivityJune 7 at 1:23 AM | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Reaches New 12-Month High - Should You Buy?Regulus Therapeutics (NASDAQ:RGLS) Hits New 1-Year High - Here's WhyJune 6, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Insider Buys $95,880.00 in StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) insider Preston Klassen acquired 12,000 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average price of $7.99 per share, for a total transaction of $95,880.00. Following the acquisition, the insider now directly owns 48,055 shares of the company's stock, valued at approximately $383,959.45. The trade was a 33.28% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.June 5, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Sees Large Volume Increase Following Insider Buying ActivityRegulus Therapeutics (NASDAQ:RGLS) Sees Strong Trading Volume on Insider Buying ActivityJune 5, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 SharesJune 5, 2025 | insidertrades.comInsider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)June 4, 2025 | gurufocus.comRegulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 PayoutJune 4, 2025 | seekingalpha.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest UpdateRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 1,910,000 shares, a decrease of 29.5% from the April 30th total of 2,710,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 1.0 days. Approximately 3.3% of the shares of the stock are sold short.June 2, 2025 | marketbeat.comMillennium Management LLC Raises Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)Millennium Management LLC lifted its stake in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 69.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,192,158 shares of the biopharmaceutical company's stock aJune 1, 2025 | marketbeat.comNorthern Trust Corp Sells 40,071 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)Northern Trust Corp reduced its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 8.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 457,233 shares of the biopharmaceutical company's stJune 1, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Hold" from BrokeragesRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and two have given a buy recoMay 26, 2025 | marketbeat.comVelan Capital Investment Management LP Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)Velan Capital Investment Management LP bought a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 70,000 shares of the biopharmMay 22, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $47,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)Price T Rowe Associates Inc. MD cut its stake in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 98.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 29,597 shares of the biopharmaceutical company's stocMay 21, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Earns Sell Rating from Analysts at StockNews.comStockNews.com assumed coverage on shares of Regulus Therapeutics in a research note on Sunday. They issued a "sell" rating for the company.May 20, 2025 | marketbeat.comOctagon Capital Advisors LP Acquires 585,101 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)Octagon Capital Advisors LP grew its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,848,802 shares of the biopharmaMay 15, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.comStockNews.com started coverage on shares of Regulus Therapeutics in a report on Saturday. They set a "sell" rating for the company.May 12, 2025 | marketbeat.comRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 9, 2025 | finanznachrichten.deRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 8, 2025 | prnewswire.comWhat is Leerink Partnrs' Estimate for RGLS Q1 Earnings?Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Regulus Therapeutics in a research note issued on Wednesday, April 30th. Leerink Partnrs analyst J. Schwartz anticipates that the biopharmaceutical company will eMay 6, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 111,485 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)JPMorgan Chase & Co. grew its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 141.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,457 shares of the biopharmaceutMay 5, 2025 | marketbeat.comREGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLSMay 4, 2025 | businesswire.comNovartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion DealMay 4, 2025 | gurufocus.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short InterestRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,110,000 shares, a decrease of 20.7% from the March 31st total of 2,660,000 shares. Approximately 4.0% of the shares of the company are sold short. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is currently 1.7 days.May 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Lowered to "Hold" Rating by Wells Fargo & CompanyWells Fargo & Company cut shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday.May 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Downgraded to "Hold" Rating by Leerink PartnrsLeerink Partnrs lowered Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday.May 4, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by RA Capital Management L.P.RA Capital Management L.P. trimmed its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 56.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 336,843 shares of the biopharmaceuticMay 3, 2025 | marketbeat.comRegulus Therapeutics (RGLS) Projected to Post Earnings on ThursdayRegulus Therapeutics (NASDAQ:RGLS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-regulus-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comWells Fargo Downgrades Regulus Therapeutics (RGLS)May 2, 2025 | msn.comNovartis to buy Regulus Therapeutics for as much as $1.7 billionMay 2, 2025 | latimes.comRegulus Therapeutics (NASDAQ:RGLS) Shares Pass Above 200-Day Moving Average - Here's What HappenedRegulus Therapeutics (NASDAQ:RGLS) Shares Pass Above 200-Day Moving Average - Here's WhyMay 2, 2025 | marketbeat.comJones Trading Downgrades Regulus Therapeutics (RGLS)May 1, 2025 | msn.comNovartis Acquires Regulus Therapeutics for $800 MillionMay 1, 2025 | gurufocus.comNovartis to Acquire Regulus Therapeutics in $1.7 Billion DealMay 1, 2025 | gurufocus.comRegulus Therapeutics Acquisition By Novartis Due To Key Farabursen AdvancementsApril 30, 2025 | seekingalpha.comRegulus Therapeutics Inc.: Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AGApril 30, 2025 | finanznachrichten.deRegulus Therapeutics stock soars on acquisition deal with NovartisApril 30, 2025 | za.investing.comNovartis to buy kidney disease drug maker Regulus in up to $1.7 billion dealApril 30, 2025 | msn.comRegulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From NovartisApril 30, 2025 | msn.comRegulus Therapeutics Acquisition By Novartis Due To Key Farabursen AdvancementsApril 30, 2025 | seekingalpha.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLSApril 30, 2025 | prnewswire.comCrude Oil Falls Over 3%; Regulus Therapeutics Shares Spike HigherApril 30, 2025 | benzinga.comNovartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 MillionApril 30, 2025 | benzinga.comRGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics ...April 30, 2025 | gurufocus.comNovartis (NVS) to Acquire Regulus Therapeutics in $0.8B Deal | NVS Stock NewsApril 30, 2025 | gurufocus.comNovartis (NVS) to Acquire Regulus Therapeutics for $0.8BApril 30, 2025 | gurufocus.comShareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. ...April 30, 2025 | gurufocus.comShareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public ShareholdersApril 30, 2025 | businesswire.comNovartis to buy Regulus Therapeutics for up to $1.7 billionApril 30, 2025 | reuters.comNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failureApril 30, 2025 | globenewswire.com Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address RGLS Media Mentions By Week RGLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼1.260.68▲Average Medical News Sentiment RGLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼93▲RGLS Articles Average Week Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ligand Pharmaceuticals News Amicus Therapeutics News Celldex Therapeutics News Innoviva News MannKind News Dynavax Technologies News Novavax News OPKO Health News Geron News Zenas Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGLS Stock Free RGLS Stock Alerts